HK Stock Connect Daily Report: MICOT PHARMA-B Rises 29.82% on Completion of Phase III Trial for MT1013 - 20261109

I. Market Overview

On November 9, 2026, the three major Hong Kong indices opened higher across the board, faded after an early push, turned lower in the afternoon and closed near the session low, with all three posting modest losses. The Hang Seng Index closed at 24,448.95, down 0.13%; the Hang Seng TECH Index closed at 4,040.73, down 0.92%; and the Hang Seng China Enterprises Index closed at 8,260.15, down 0.17%. Full-day turnover on the Hang Seng Index reached HKD 173.7 billion, notably below HKD 247.4 billion a day earlier.

On the board, among Stock Connect constituent stocks, MICOT PHARMA-B rose 29.82%, FAMEGLOW rose 27.86%, GALAXIS TECH rose 15.05%, ZAI LAB rose 14.16% and VIEWTRIX TECH rose 13.79%; on the downside, FIT HON TENG fell 12.54%, CFMEE fell 12.45%, LIFETECH SCI fell 11.14%, LOGAN GROUP fell 9.33% and KB LAMINATES fell 9.21%. Innovative drug and coal names led the gains, while connector, semiconductor equipment and copper clad laminate names, all part of the AI hardware chain, lagged, with property and medical device names also weaker. Across the Stock Connect universe, 277 stocks rose, 368 fell and 21 were unchanged.

Southbound capital recorded net buying of HK$1.856 billion on the day, comprising net buying of HK$1.049 billion via Stock Connect (Shanghai) and HK$807 million via Stock Connect (Shenzhen).

II. HK Stock Connect Stock Rankings

2.1 HK Stock Connect Stock Gainers and Decliners

Source: Wind, HKEX. The content of this article is for the objective presentation of data only and does not constitute any investment advice, nor does it represent a recommendation for or value judgment on any security. The market involves risks; investment requires caution.

2.2 HK Stock Connect Active Stocks (ranked by southbound turnover)

Source: Wind, HKEX. The content of this article is for the objective presentation of data only and does not constitute any investment advice, nor does it represent a recommendation for or value judgment on any security. The market involves risks; investment requires caution.

III. HK Stock Connect-related A-share ETF Rankings

3.1 HK Stock Connect-related A-share ETF Gainers and Decliners

Source: Wind. The content of this article is for the objective presentation of data only and does not constitute any investment advice, nor does it represent a recommendation for or value judgment on any security. The market involves risks; investment requires caution.

3.2 HK Stock Connect-related A-share ETF Active Rankings (ranked by turnover)

Source: Wind. The content of this article is for the objective presentation of data only and does not constitute any investment advice, nor does it represent a recommendation for or value judgment on any security. The market involves risks; investment requires caution.

IV. Industry and Corporate Updates

1. Southbound Net Buying Reaches HK$1.856 Billion as MEITUAN-W Leads with HK$592 Million

On November 9, southbound capital recorded net buying of HK$1.856 billion, comprising net buying of HK$1.049 billion via Stock Connect (Shanghai) and HK$807 million via Stock Connect (Shenzhen). By stock, MEITUAN-W (03690.HK) led with HK$592 million of net buying, followed by CHINA MOBILE (00941.HK) at HK$242 million, CNOOC (00883.HK) at HK$200 million, XIAOMI-W (01810.HK) at HK$99 million and UBTECH ROBOTICS (09880.HK) at HK$76 million. On the sell side, TENCENT (00700.HK) saw HK$322 million of net selling, Z.AI (02513.HK) HK$111 million and HUA HONG GRACE (01347.HK) HK$74 million. No broad-based Hong Kong ETF appeared in the top ten by southbound turnover, where KB LAMINATES (01888.HK) ranked first at HK$2.915 billion.

2. MICOT PHARMA-B Jumps 29.82% as Pivotal Phase III Trial of MT1013 Completes Last Patient Out

On November 9, MICOT PHARMA-B (02335.HK) announced that in the pivotal Phase III clinical trial of its core product MT1013, all enrolled participants had completed study treatment and all protocol-required follow-up procedures and had exited the study; the trial enrolled 435 patients in total. The primary endpoint is the proportion of patients in each arm whose serum iPTH levels fall by more than 50% and more than 30% from baseline during the efficacy assessment period. The company said no new major safety signals had emerged from the safety monitoring data available so far; remaining work includes data cleaning, database lock, unblinding and statistical analysis, and should the results support a filing, the company plans to submit a new drug application for MT1013 to the National Medical Products Administration. The stock closed up 29.82% at HK$24.42 on turnover of HK$276 million.

3. ZAI LAB Rises 14.16% on Third-Quarter Product Revenue of USD 107.6 Million

On November 9, Hong Kong biotechnology names opened higher across the board. ZAI LAB (09688.HK) closed up 14.16% at HK$20.96 on turnover of HK$212 million, with AKESO up 4.05% and ASCENTAGE and BEONE MEDICINES also higher. The company reported third-quarter 2026 total revenue of USD 108.2 million, of which net product revenue was USD 107.6 million, up 2% quarter on quarter, driven mainly by wider coverage and penetration of its core product and contributions from a newly launched product. Founder, Chairman and Chief Executive Officer Samantha Du said strong data on zoci in first-line combination therapy presented at ESMO reinforced confidence in its potential as a cornerstone ADC for small cell lung cancer. On November 6, the company presented clinical data at NANETS for zoci in extrapulmonary neuroendocrine carcinoma, with a confirmed objective response rate of 40%.

4. SHOUGANG RES Gains 12.94% as Special Dividend Expectations Lift Coal Stocks

On November 9, Hong Kong coal stocks advanced against the market trend. SHOUGANG RES (00639.HK) closed up 12.94% at HK$2.88 on turnover of HK$143 million, while Yankuang Energy rose 6.34%, China Coal Energy 4.84% and China Shenhua more than 3%. SHOUGANG RES said after the close on November 6 that its board will meet on November 18 to consider approving the declaration and payment of a special dividend to shareholders, the main company-specific catalyst behind the move. At the sector level, coal prices have stopped falling and rebounded recently, lifting sentiment across the sector.

5. China-Korea Semiconductor ETF Tops Turnover at RMB 8.584 Billion as Nasdaq Biotechnology ETF Leads Gainers at 2.87%

On November 9, Stock Connect-related ETFs diverged. The Huatai-PB China Securities Han Stock Exchange China Korea Semiconductor ETF(QDII) (513310) fell 0.93% on RMB 8.584 billion of turnover and a turnover rate of 90.97%, topping the turnover list; the GF CSI HK Innovative Drugs Industry ETF(QDII) (513120) rose 1.69% on RMB 6.732 billion, ranking second; and the ChinaAMC Hang Seng Technology ETF(QDII) (513180) fell 0.39% on RMB 2.630 billion. On the gainer side, the China Universal Nasdaq Biotechnology ETF(QDII) (513290) rose 2.87%, the China Southern TOPIX ETF(QDII) (513800) rose 2.45%, the E Fund Itaú Unibanco IBOVESPA ETF(QDII) (520870) rose 2.37% and the Harvest S&P Biotechnology Select Industry ETF(QDII) (159502) rose 2.35%. On the decliner side, the Guotai CSI HK Equities Internet ETF (513720) fell 1.13%, the Fullgoal Hang Seng HK Automobile Theme ETF (159239) fell 1.07% and the Fullgoal S&P Oil & Gas Exploration and Production Selected Industry ETF(QDII) (513350) fell 0.95%.